Investor Contact Information: Rafael Tejada Thermo Fisher Scientific E-mail: sandy.pound@thermofisher.com E-mail: rafael.tejada@thermofisher.com Exhibit 99.1 News Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results WALTHAM, Mass. (January 29, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth qu ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights "Thanks to our exceptional team, we delivered a strong finish to 2025, reflecting outstanding execution and the continued strength of our proven growth strategy,†said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scienti ...

摘要 ： "3i奖-优秀新品"二十年来，累计评选出年度优秀新品429台，质谱类以76台获奖位列第一。 高分辨质谱技术在很大程度上解决了传统质谱技术在蛋白质分析中面临灵敏度不足、分辨率有 限、通量低下三大瓶颈，能够实现复杂生物样本中数千种蛋白质组成解析、低丰度蛋白识别、 翻译后修饰（如磷酸化、糖基化）准确测定。 2011 年 赛 默 飞 推 出 Orbitrap El ite ， 将 扫 描 速 度 提 升 至 每 秒 12 张 高 分 辨 谱 图 。 2014 年 SCIEX的TripleTOF 6600系统则通过超快扫描技术实现了数据非依赖采集，使单次进样可定 量数千种蛋白质；该仪器也将代谢物鉴定从几百种扩展到数千种，覆盖了氨基酸、有机酸、脂 质 、 激 素 等 几 乎 所 有 代 谢 物 类 别 。 2018 年 SCIEX 的 M5 Microflow LC - OptiFlow™Turbo V源集成化高灵敏度质谱系统将纳流色谱与质谱联用，显著提高了蛋白质 序列覆盖率和修饰位点鉴定准确性。2019年赛默飞的Orbitrap Ecl ipse引入了实时搜索、智 能 碎 裂 等 AI 算 法 ， 将 质 谱 ...

Core Viewpoint - Thermo Fisher Scientific Inc. is poised to report strong quarterly earnings, with anticipated growth in both earnings per share and revenue, reflecting its robust market position and demand for its products [1][2]. Financial Performance - Analysts expect Thermo Fisher to report an earnings per share (EPS) of $6.43, representing a 5.4% increase from the same period last year [2][6]. - Projected revenue is approximately $11.94 billion, indicating a 4.8% year-over-year growth [2][6]. Market Reactions - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the past month, which may influence short-term stock price movements [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 35.90, indicating strong investor confidence in future growth prospects [4][6]. - The price-to-sales (P/S) ratio stands at about 5.36, reflecting the value placed on each dollar of sales [4][6]. - The enterprise value to sales ratio is around 6.13, and the enterprise value to operating cash flow ratio is approximately 35.04, highlighting the company's valuation in relation to its sales and cash flow [5]. Financial Health - Thermo Fisher maintains a debt-to-equity ratio of approximately 0.70, indicating a moderate level of debt compared to its equity [5]. - A current ratio of about 1.50 suggests good liquidity to cover short-term liabilities [5].

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named BlackRock, Inc. (NYSE:BLK) as his final trade.BlackRock, on Jan. 15, reported better-than-expected fourth-quarter financial results and raised its quarterly dividend. Revenue grew 23% year-over-year (Y/Y) to $7.01 billion, beating the consensus of $6.69 billion. Adjusted operating income rose 22% Y/Y to $2.85 billion. Adjusted EPS increased 10% Y/Y to $13.16, beating the consensus of $12.25.Stephen Weiss, chief invest ...

The upcoming report from Thermo Fisher Scientific (TMO) is expected to reveal quarterly earnings of $6.43 per share, indicating an increase of 5.4% compared to the year-ago period. Analysts forecast revenues of $11.94 billion, representing an increase of 4.8% year over year.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts ov ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近 日 ， " 2 0 2 6 年 全 球 品 牌 价 值 5 0 0 强 " 榜 单 (Gl o b a l 5 0 0 2 0 2 6 ) 由 英 国 品 牌 评 估 机 构 " 品 牌 金 融"（Br a n d Fi n a n c e） 在 瑞士达沃斯世界经济论坛 上发布，苹果、微软、谷歌、亚马逊位居 前四，英伟达升至第五名。 每年 ， Br a n d Fi n a n c e会对全球规模前5 0 0 0的品牌进行估值 ， 并发布1 0 0多份报告 ， 对 各 行业和各国家 、 地区的品牌进行排名 。 品牌价值被理解为品牌所有者通过在公开市场上许可 该品牌所获得的净经济收益 。 值得一提的是，继2 0 2 3年上榜（No . 4 6 9）之后，时隔两年， 赛默飞在今年重新以排名4 5 4的 成绩回到榜单之上，同时也成为榜上唯一以科学仪器为主营业务的品牌 。 此外， 美的、海尔、 罗氏、日立、 西门子、通用电气（GE）、飞利浦、雅培 这些涉及仪器 业务的知名品牌也在5 0 0强榜单 ...

Core Insights - Thermo Fisher Scientific Inc. (TMO) is set to release its fourth-quarter 2025 results on January 29, with earnings per share (EPS) expected to be $6.44, reflecting a 5.6% growth year-over-year [1][2][9] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for TMO's revenues is $11.95 billion, indicating a 4.9% increase from the same quarter last year [2][9] - TMO's earnings have consistently beaten estimates in the past four quarters, with an average surprise of 2.95% [1] Group 2: Segment Performance - The Analytical Instruments segment is anticipated to generate strong sales, particularly from electron microscopy and chromatography and mass spectrometry businesses [4] - The Life-Science Solutions segment is expected to report $2.89 billion in revenues, representing an 11.1% year-over-year improvement, driven by growth in the bioproduction business [10] - Specialty Diagnostics sales are projected to rise by 4.8% year-over-year, supported by new FDA approvals and product launches [9][13] Group 3: Recent Developments - TMO launched several new products, including the Orbitrap Exploris EFOX Mass Detector and new formulations for plasmid DNA production, which are expected to positively impact quarterly revenues [5][7] - The acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion is also anticipated to contribute favorably to TMO's performance [8] - TMO received FDA approvals for multiple diagnostic tests and launched new automated platforms, which are expected to enhance its top-line performance [11][12]

Wall Street expects a year-over-year increase in earnings on higher revenues when Thermo Fisher Scientific (TMO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 29, might help the stock move higher if these key numbers are better ...

Core Thesis - Thermo Fisher Scientific Inc. (TMO) is positioned as a strong investment opportunity in the healthcare and pharmaceutical sectors, benefiting from structural demand and a unique business model that minimizes risks associated with drug development [2][3]. Company Overview - Thermo Fisher provides a wide range of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services globally, making it a key player in the healthcare innovation landscape [2]. - The company commands approximately 15% of the global life sciences tools and services market, forming a duopoly with Danaher [3]. Market Dynamics - The healthcare demand is resilient due to aging populations, rising chronic diseases, and increased healthcare spending in emerging markets, which supports long-term growth for companies like Thermo Fisher [2]. - The shift towards more complex medicine, including biologics and precision therapies, increases the demand for infrastructure providers, positioning Thermo Fisher favorably within the ecosystem [3]. Business Model - Thermo Fisher's business model focuses on embedding itself throughout the drug development lifecycle, which reduces exposure to patent cliffs and demand volatility [4]. - The company generates significant revenue from high-margin consumables tied to its installed base, creating a recurring revenue stream that enhances financial stability [4]. Financial Performance - Recent operational results indicate improving fundamentals, with the company experiencing positive organic growth and an acceleration in demand from the pharmaceutical and biotech sectors [5]. - The disciplined approach to mergers and acquisitions (M&A) is a core value driver, enhancing capabilities and supporting robust free cash flow, which benefits shareholder returns [5].